Nielsen Kirk G. 的 Form 4/A 修正申報
修正SpyGlass Pharma, Inc.（SGP），2026/2/11 申報
- 申報編號
- 0001193125-26-046833
- 申報時間
- 2026/2/11
- 交易日
- 2026/2/9
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2026/2/10
這份申報列了 4 筆衍生性交易。沿用原件裡沒有重述的 5 筆交易。公開市場買進合計 $264.0 萬。交易後 2 天申報。
這份修正申報重述了 0001193125-26-045029（2026/2/10 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Nielsen Kirk G.CIK 0001523522 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
這份申報沒有這一類的交易。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001193125-26-045029（2026/2/10 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/2/9 | Common Stock | C轉換取得 | +1,690,230 | –F1 | – | 1,690,230 | 間接 | |
| 2026/2/9 | Common Stock | C轉換取得 | +548,067 | –F1 | – | 2,238,297 | 間接 | |
| 2026/2/9 | Common Stock | C轉換取得 | +548,067 | –F1 | – | 2,786,364 | 間接 | |
| 2026/2/9 | Common Stock | C轉換取得 | +359,255 | –F1 | – | 3,145,619 | 間接 | |
| 2026/2/9 | Common Stock | P買進取得 | +165,000 | $16.00 | +$2,640,000 | 3,310,619 | 間接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F1
Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
表 I 有 4 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date.
表 II 有 4 筆交易的價格引用這則附註。
- F2
These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
備註
This amended Form 4 amends and restates Table II of the Form 4 filed by the Reporting Person on February 10, 2026 (the "Prior Form 4") and is being filed to correct the number of shares reported in Column 5 of Table II of the Prior Form 4 to reflect the Issuer's preferred stock converted on a one-for-one basis into shares of the Issuer's Common Stock prior to the closing of the Issuer's initial public offering of its Common Stock.